ASLAN Hosts Oncology Symposium For Investors

Published: Sep 26, 2017

Taipei, Taiwan, 26 September 2017 – ASLAN Pharmaceuticals (ASLAN, 6497.TT), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types,

Organised in partnership with Bernstein Research, KGI Securities, Taiwan Liposome Company (TLC), JHL Biotech and the Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), the symposium is targeted at investors who are interested in oncology, with an aim to help improve their understanding of this complex domain. The symposium is aimed at generalist investors, as well as first time biotech investors.

Leading clinicians and industry veterans speaking at symposium include:

• Hong Jen Chang, Chairman, TRPMA;

• Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals;

• Dr Laura Nelson Carney, Senior Research Analyst, Bernstein Research;

• Professor Tsu-Yi Chao, Chair and Professor of Haematology and Oncology at Shuang-Ho Hospital, Taipei Medical University;

• Professor Hui-Chuan Sun, Deputy Head, Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongsan Hospital, Fudan University;

• Dr Yao-Yu Hsieh, Attending Physician of Haematology and Oncology at Shuang-Ho Hospital, Taipei Medical University; and

• Dr Chih-Yi Hsieh, Vice President (Medical) and General Manager (Taiwan), ASLAN Pharmaceuticals. No company information will be shared at this event.


Media contacts
Chris Fang
ASLAN Pharmaceuticals
Tel: +886 2 2758 3333

Emma Thompson / Stephanie Tan
Spurwing Communications
Tel: +65 6340 7287

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (6497.TT) is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform that reaches across the region via its offices in Taiwan, China and Australia. The Company is developing 5 drugs addressing multiple indications including biliary tract cancer, gastric cancer and colorectal cancer, and has two global pivotal studies in biliary tract cancer and gastric cancer underway. ASLAN’s partners include Array BioPharma, Bristol-Myers Squibb, Almirall and CSL.

Back to news